메뉴 건너뛰기




Volumn 59, Issue 4, 2011, Pages 237-245

Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of Type 2 diabetes

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; NITRILE; PYRROLIDINE DERIVATIVE; VILDAGLIPTIN;

EID: 79955506305     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (11)

References (84)
  • 1
    • 73749083481 scopus 로고    scopus 로고
    • Global estimates of the prevalence of diabetes for 2010 and 2030
    • Shaw JE, Sicree RA, Zimmet PZ.; Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4-14.
    • (2010) Diabetes Res Clin Pract , vol.87 , pp. 4-14
    • Shaw, J.E.1    Sicree, R.A.2    Zimmet, P.Z.3
  • 2
    • 19444371063 scopus 로고    scopus 로고
    • International Diabetes Federation, third edition
    • International Diabetes Federation. Diabetes atlas: executive summary third edition
    • Diabetes atlas: Executive summary
  • 3
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
    • UK Prospective Diabetes Study (UKPDS) Group
    • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 4
    • 0029147687 scopus 로고
    • Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
    • Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
    • (1995) Diabetes Res Clin Pract , vol.28 , pp. 103-117
    • Ohkubo, Y.1    Kishikawa, H.2    Araki, E.3
  • 5
    • 1042280201 scopus 로고    scopus 로고
    • Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report
    • Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20.
    • (2004) Diabetes Care , vol.27 , pp. 17-20
    • Koro, C.E.1    Bowlin, S.J.2    Bourgeois, N.3    Fedder, D.O.4
  • 6
    • 12444289448 scopus 로고    scopus 로고
    • Oral antihyperglycemic therapy for type 2 diabetes mellitus
    • Cheng AY, Fantus IG.; Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-26.
    • (2005) CMAJ , vol.172 , pp. 213-226
    • Cheng, A.Y.1    Fantus, I.G.2
  • 7
    • 0037116638 scopus 로고    scopus 로고
    • Oral antihyperglycemia therapy for type 2 diabetes: Scientific review
    • Inzucchi SE. Oral antihyperglycemia therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002;287:360-72.
    • (2002) J Am Med Assoc , vol.287 , pp. 360-372
    • Inzucchi, S.E.1
  • 8
    • 84860117993 scopus 로고    scopus 로고
    • Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database
    • Tzoulaki I et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;3:339.
    • (2009) BMJ , vol.3 , pp. 339
    • Tzoulaki, I.1
  • 9
    • 67349203256 scopus 로고    scopus 로고
    • The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: A retrospective analysis
    • Pantalone KM et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009;46:145-54.
    • (2009) Acta Diabetol , vol.46 , pp. 145-154
    • Pantalone, K.M.1
  • 10
    • 67650465654 scopus 로고    scopus 로고
    • Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: A retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan
    • Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW.; Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 2009;32:675-90.
    • (2009) Drug Saf , vol.32 , pp. 675-690
    • Hsiao, F.Y.1    Huang, W.F.2    Wen, Y.W.3    Chen, P.F.4    Kuo, K.N.5    Tsai, Y.W.6
  • 11
    • 34250212715 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
    • Nissen SE, Wolski K.; Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
    • (2007) N Engl J Med , vol.356 , pp. 2457-2471
    • Nissen, S.E.1    Wolski, K.2
  • 12
    • 0023629132 scopus 로고
    • Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics
    • Cohen KL, Harris S. Efficacy of glyburide in diabetics poorly controlled on first-generation oral hypoglycemics. Diabetes Care 1987;10:555-557.
    • (1987) Diabetes Care , vol.10 , pp. 555-557
    • Cohen, K.L.1    Harris, S.2
  • 13
    • 79955499161 scopus 로고    scopus 로고
    • Robert S. Dinsmoor; http://www.diabetesselfmanagement.com/articles/diabetesdefinitions/sulfonylureas/print/
    • Dinsmoor
    • Robert, S.1
  • 15
    • 0031927337 scopus 로고    scopus 로고
    • A placebo controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful
    • Schade DS, Jovanovic L, Schneider J. A placebo controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-641.
    • (1998) J Clin Pharmacol , vol.38 , pp. 636-641
    • Schade, D.S.1    Jovanovic, L.2    Schneider, J.3
  • 16
    • 0027066928 scopus 로고
    • Glyburide versus glipizide in the treatment of patients with noninsulin-dependent diabetes mellitus
    • Kilo C, Meenan A, Bloomgaren Z. Glyburide versus glipizide in the treatment of patients with noninsulin-dependent diabetes mellitus. Clin Ther 1992;14:801-812.
    • (1992) Clin Ther , vol.14 , pp. 801-812
    • Kilo, C.1    Meenan, A.2    Bloomgaren, Z.3
  • 17
    • 0024515411 scopus 로고
    • Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents
    • Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989;12:203-208.
    • (1989) Diabetes Care , vol.12 , pp. 203-208
    • Jennings, A.M.1    Wilson, R.M.2    Ward, J.D.3
  • 18
    • 0024586640 scopus 로고
    • Drug-induced hypoglycemia: A review of 1418 cases
    • Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin 1989;18:163-183.
    • (1989) Endocrinol Metab Clin , vol.18 , pp. 163-183
    • Seltzer, H.S.1
  • 19
    • 0002390349 scopus 로고    scopus 로고
    • The British Diabetic Association cohort study, II: Cause-specific mortality in patients with insulin-treated diabetes mellitus
    • Laing SP, Swerdlow AJ, Slater SD et al. The British Diabetic Association cohort study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 1999;16:466-71.
    • (1999) Diabet Med , vol.16 , pp. 466-471
    • Laing, S.P.1    Swerdlow, A.J.2    Slater, S.D.3
  • 20
    • 0842270123 scopus 로고    scopus 로고
    • Long-acting sulfonylureas-long-acting hypoglycaemia
    • Veitch PC, Clifton-Bligh RJ. Long-acting sulfonylureas-long-acting hypoglycaemia. Med J Aust 2004;180:84-5.
    • (2004) Med J Aust , vol.180 , pp. 84-85
    • Veitch, P.C.1    Clifton-Bligh, R.J.2
  • 21
    • 0034844049 scopus 로고    scopus 로고
    • The WHO Multinational Study Group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
    • Morrish NJ, Wang SL, Stevens LK et al. The WHO Multinational Study Group. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 2001;44:s14-s21.
    • (2001) Diabetologia , vol.44
    • Morrish, N.J.1    Wang, S.L.2    Stevens, L.K.3
  • 23
    • 77952662113 scopus 로고    scopus 로고
    • Does hypoglycaemia cause cardiovascular events?
    • Graveling AJ, Frier BM. Does hypoglycaemia cause cardiovascular events? Br J Diabetes Vasc Dis 2010;10:5-13.
    • (2010) Br J Diabetes Vasc Dis , vol.10 , pp. 5-13
    • Graveling, A.J.1    Frier, B.M.2
  • 24
    • 31544482787 scopus 로고    scopus 로고
    • Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: A population-based cohort study
    • Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-174
    • (2006) CMAJ , vol.174 , pp. 169-174
    • Simpson, S.H.1    Majumdar, S.R.2    Tsuyuki, R.T.3
  • 25
    • 0031840144 scopus 로고    scopus 로고
    • Possible risk of sulphonylureas in the treatment of noninsulin- dependent diabetes mellitus and coronary artery disease
    • Fasching P.; Possible risk of sulphonylureas in the treatment of noninsulin- dependent diabetes mellitus and coronary artery disease. Diabetologia 1998;41:743-4.
    • (1998) Diabetologia , vol.41 , pp. 743-744
    • Fasching, P.1
  • 26
    • 12244268666 scopus 로고    scopus 로고
    • On the physiology of GIP and GLP-1
    • Holst J.J: On the physiology of GIP and GLP-1. Horm Metab Res 2004;36:747-754
    • (2004) Horm Metab Res , vol.36 , pp. 747-754
    • Holst, J.J.1
  • 27
    • 33644842108 scopus 로고    scopus 로고
    • Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes
    • Deacon C.F and J.J. Holst: Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 2006;38:831-844
    • (2006) Int J Biochem Cell Biol , vol.38 , pp. 831-844
    • Deacon, C.F.1    Holst, J.J.2
  • 28
    • 4344675057 scopus 로고    scopus 로고
    • Therapeutic strategies based on glucagonlike peptide-1
    • Deacon CF: Therapeutic strategies based on glucagonlike peptide-1. Diabetes 2004;53:2181-2189.
    • (2004) Diabetes , vol.53 , pp. 2181-2189
    • Deacon, C.F.1
  • 29
    • 33748438730 scopus 로고    scopus 로고
    • Incretin mimetics and dipeptidyl peptidase-IV inhibitors: A review of emerging therapies for type 2 diabetes
    • Kendall DM, Kim D, Maggs D.; Incretin mimetics and dipeptidyl peptidase-IV inhibitors: a review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 2006;8:385-96.
    • (2006) Diabetes Technol Ther , vol.8 , pp. 385-396
    • Kendall, D.M.1    Kim, D.2    Maggs, D.3
  • 30
    • 33644676141 scopus 로고    scopus 로고
    • Incretins mimetics and dipeptidyl peptidase-IV inhibitors: Potential new therapies for type 2 diabetes mellitus
    • Triplitt C, Wright A, Chiquette E.; Incretins mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus. Pharmacotherapy 2006;26:360-74.
    • (2006) Pharmacotherapy , vol.26 , pp. 360-374
    • Triplitt, C.1    Wright, A.2    Chiquette, E.3
  • 31
    • 0031690479 scopus 로고    scopus 로고
    • Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes
    • Holst JJ, Deacon CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998;47:1663-1670.
    • (1998) Diabetes , vol.47 , pp. 1663-1670
    • Holst, J.J.1    Deacon, C.F.2
  • 32
    • 15044362439 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes
    • Nauck MA, Meier JJ. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005;124(suppl):135-48.
    • (2005) Regul Pept , vol.124 , Issue.SUPPL. , pp. 135-148
    • Nauck, M.A.1    Meier, J.J.2
  • 33
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing Incretin Action for the Treatment of Type 2 Diabetes
    • Drucker DJ. Enhancing Incretin Action for the Treatment of Type 2 Diabetes. Diabetes Care 2003;26:2929-40.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 34
    • 16244385334 scopus 로고    scopus 로고
    • Exenatide: A novel treatment of type 2 diabetes
    • Ahrén B: Exenatide: a novel treatment of type 2 diabetes. Therapy 2005;2:207-22.
    • (2005) Therapy , vol.2 , pp. 207-222
    • Ahrén, B.1
  • 35
    • 33645707285 scopus 로고    scopus 로고
    • Vildagliptin: An inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
    • Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006;15:431-42.
    • (2006) Expert Opin Investig Drugs , vol.15 , pp. 431-442
    • Ahren, B.1
  • 36
    • 20444406121 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3- hydroxyadamanta- 1-yl) amino]acetyl}-pyrrolidine-2- carbonitrile)
    • Brandt I, Joossens J, Chen X et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[(3- hydroxyadamanta- 1-yl) amino]acetyl}-pyrrolidine-2- carbonitrile). Biochem Pharmacol 2005;70:134-43.
    • (2005) Biochem Pharmacol , vol.70 , pp. 134-143
    • Brandt, I.1    Joossens, J.2    Chen, X.3
  • 37
    • 28844482322 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
    • Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 675-688
    • Herman, G.A.1    Stevens, C.2    Van Dyck, K.3
  • 38
    • 34147208931 scopus 로고    scopus 로고
    • Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT analyses
    • He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT analyses. J Clin Pharmacol 2007;47:633-41.
    • (2007) J Clin Pharmacol , vol.47 , pp. 633-641
    • He, Y.L.1    Wang, Y.2    Bullock, J.M.3
  • 39
    • 27744540889 scopus 로고    scopus 로고
    • Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response
    • Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7:692-8.
    • (2005) Diabetes Obes Metab , vol.7 , pp. 692-698
    • Ristic, S.1    Byiers, S.2    Foley, J.3
  • 40
    • 33745903093 scopus 로고    scopus 로고
    • Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    • Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8.
    • (2006) Horm Metab Res , vol.38 , pp. 423-428
    • Pratley, R.E.1    Jauffret-Kamel, S.2    Galbreath, E.3
  • 41
    • 9444285818 scopus 로고    scopus 로고
    • Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    • Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80.
    • (2004) Diabetes Care , vol.27 , pp. 2874-2880
    • Ahren, B.1    Gomis, R.2    Standl, E.3
  • 42
    • 55049090992 scopus 로고    scopus 로고
    • Vildagliptin: A review of its use in the management of type 2 diabetes mellitus
    • Croxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008;68:2387-409.
    • (2008) Drugs , vol.68 , pp. 2387-2409
    • Croxtall, J.D.1    Keam, S.J.2
  • 45
    • 34548324787 scopus 로고    scopus 로고
    • The absolute oral bioavailability and population-based pharmacokinetic modeling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
    • He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and population-based pharmacokinetic modeling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46:787-802.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 787-802
    • He, Y.L.1    Sadler, B.M.2    Sabo, R.3
  • 46
    • 33751098267 scopus 로고    scopus 로고
    • Vildagliptin
    • Henness S, Keam SJ. Vildagliptin. Drugs 2006;66:1989-2001.
    • (2006) Drugs , vol.66 , pp. 1989-2001
    • Henness, S.1    Keam, S.J.2
  • 47
    • 58349115426 scopus 로고    scopus 로고
    • Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
    • Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H.; Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83:233-40.
    • (2009) Diabetes Res Clin Pract , vol.83 , pp. 233-240
    • Kikuchi, M.1    Abe, N.2    Kato, M.3    Terao, S.4    Mimori, N.5    Tachibana, H.6
  • 48
    • 55049126852 scopus 로고    scopus 로고
    • Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes mellitus: Superior efficacy and tolerability with vildagliptin [abstract no. 561-P]
    • San Francisco (CA)
    • Iwamoto Y, Kashiwagi A, Yamada N, et al. Vildagliptin versus voglibose monotherapy in patients with type 2 diabetes mellitus: superior efficacy and tolerability with vildagliptin [abstract no. 561-P]. 68th Annual Scientific Sessions of the American Diabetes Association 2008; San Francisco (CA)
    • (2008) 68th Annual Scientific Sessions of the American Diabetes Association
    • Iwamoto, Y.1    Kashiwagi, A.2    Yamada, N.3
  • 49
    • 33745903093 scopus 로고    scopus 로고
    • Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    • Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423-8.
    • (2006) Horm Metab Res , vol.38 , pp. 423-428
    • Pratley, R.E.1    Jauffret-Kamel, S.2    Galbreath, E.3    Holmes, D.4
  • 50
    • 41749106662 scopus 로고    scopus 로고
    • Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Pan C, Yang W, Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25:435-41.
    • (2008) Diabet Med , vol.25 , pp. 435-441
    • Pan, C.1    Yang, W.2    Barona, J.P.3
  • 51
    • 33846694046 scopus 로고    scopus 로고
    • Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-23.
    • (2007) Diabetes Care , vol.30 , pp. 217-223
    • Rosenstock, J.1    Baron, M.A.2    Dejager, S.3    Mills, D.4    Schweizer, A.5
  • 54
    • 34548118796 scopus 로고    scopus 로고
    • Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes
    • Schweizer A, Couturier A, Foley JE, Dejager S;. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med 2007;24:955-61.
    • (2007) Diabet Med , vol.24 , pp. 955-961
    • Schweizer, A.1    Couturier, A.2    Foley, J.E.3    Dejager, S.4
  • 55
    • 33846905487 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes
    • Pi-Sunyer FX, Schweizer A, Mills D, Dejager S.; Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132-8.
    • (2007) Diabetes Res Clin Pract , vol.76 , pp. 132-138
    • Pi-Sunyer, F.X.1    Schweizer, A.2    Mills, D.3    Dejager, S.4
  • 56
    • 33847687205 scopus 로고    scopus 로고
    • Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
    • Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23
    • (2007) Horm Metab Res , vol.39 , pp. 218-223
    • Dejager, S.1    Razac, S.2    Foley, J.E.3
  • 58
    • 67649933635 scopus 로고    scopus 로고
    • Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: A 24-week, double-blind, randomized trial
    • Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804-12.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 804-812
    • Schweizer, A.1    Dejager, S.2    Bosi, E.3
  • 59
    • 34147093268 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    • Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ.; Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5.
    • (2007) Diabetes Care , vol.30 , pp. 890-895
    • Bosi, E.1    Camisasca, R.P.2    Collober, C.3    Rochotte, E.4    Garber, A.J.5
  • 60
    • 33846828660 scopus 로고    scopus 로고
    • Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study
    • Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166-74.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 166-174
    • Garber, A.J.1    Schweizer, A.2    Baron, M.A.3    Rochotte, E.4    Dejager, S.5
  • 62
    • 37349054435 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study
    • Bolli G, Dotta F, Rochotte E, et al. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10:82-90.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 82-90
    • Bolli, G.1    Dotta, F.2    Rochotte, E.3
  • 64
    • 77953055922 scopus 로고    scopus 로고
    • Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy
    • Ahren B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S, Fonseca VA.; Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010;33:730-2.
    • (2010) Diabetes Care , vol.33 , pp. 730-732
    • Ahren, B.1    Foley, J.E.2    Ferrannini, E.3    Matthews, D.R.4    Zinman, B.5    Dejager, S.6    Fonseca, V.A.7
  • 65
    • 77955048324 scopus 로고    scopus 로고
    • Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: Results from a 2-year study
    • Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, et al.; Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-9.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 780-789
    • Matthews, D.R.1    Dejager, S.2    Ahren, B.3    Fonseca, V.4    Ferrannini, E.5
  • 66
    • 77949356196 scopus 로고    scopus 로고
    • A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study
    • Filozof C, Gautier JF.; A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27:318-26.
    • (2010) Diabet Med , vol.27 , pp. 318-326
    • Filozof, C.1    Gautier, J.F.2
  • 67
    • 70349761649 scopus 로고    scopus 로고
    • Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: Results of the GALIANT trial--a primary care, type 2 diabetes study
    • Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M.; Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11:978-86.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 978-986
    • Blonde, L.1    Dagogo-Jack, S.2    Banerji, M.A.3    Pratley, R.E.4    Marcellari, A.5    Braceras, R.6    Purkayastha, D.7    Baron, M.8
  • 68
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S.; Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3    Matthews, D.4    Ahrén, B.5    Byiers, S.6    Shao, Q.7    Dejager, S.8
  • 69
    • 47049084841 scopus 로고    scopus 로고
    • Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
    • Fonseca V, Baron M, Shao Q, Dejager S.; Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40:427-30.
    • (2008) Horm Metab Res , vol.40 , pp. 427-430
    • Fonseca, V.1    Baron, M.2    Shao, Q.3    Dejager, S.4
  • 71
    • 79953783720 scopus 로고    scopus 로고
    • U.S. Department of Health and Human Services: Food and Drug Administration, Available from URL:, Accessed 11 October 2010
    • U.S. Department of Health and Human Services: Food and Drug Administration. Diabetes Mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes,2008;1-5. Available from URL:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 11 October 2010.
    • (2008) Diabetes Mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes , pp. 1-5
  • 72
    • 67650747353 scopus 로고    scopus 로고
    • Cardiovascular consequences of drugs used for the treatment of diabetes: Potential promise of incretin-based therapies
    • Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009;3:245-259.
    • (2009) J Am Soc Hypertens , vol.3 , pp. 245-259
    • Ban, K.1    Hui, S.2    Drucker, D.J.3    Husain, M.4
  • 73
    • 34547930879 scopus 로고    scopus 로고
    • Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
    • Sokos GG, Bolukoglu H, German J et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007;100:824-829.
    • (2007) Am J Cardiol , vol.100 , pp. 824-829
    • Sokos, G.G.1    Bolukoglu, H.2    German, J.3
  • 74
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699.
    • (2006) J Card Fail , vol.12 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 75
    • 77953182696 scopus 로고    scopus 로고
    • Assessing the cardiocerebrovascular safety of vildagliptin: Meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
    • Schweizer A, Dejager S, Foley JE, et al. Assessing the cardiocerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab 2010;12:485-94.
    • (2010) Diabetes Obes Metab , vol.12 , pp. 485-494
    • Schweizer, A.1    Dejager, S.2    Foley, J.E.3
  • 76
    • 58149094297 scopus 로고    scopus 로고
    • Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis
    • Williams-Herman D, Round E, Swern AS et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008;8:14.
    • (2008) BMC Endocr Disord , vol.8 , pp. 14
    • Williams-Herman, D.1    Round, E.2    Swern, A.S.3
  • 78
    • 65949111736 scopus 로고    scopus 로고
    • Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes
    • Noel RA, Braun DK, Patterson RE, Bloomgren GL Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes. Diabetes Care 2009;32:834-838.
    • (2009) Diabetes Care , vol.32 , pp. 834-838
    • Noel, R.A.1    Braun, D.K.2    Patterson, R.E.3    Bloomgren, G.L.4
  • 79
  • 80
    • 72449148137 scopus 로고    scopus 로고
    • Glucagonlike peptide-1 therapy and the exocrine pancreas: Innocent bystander or friendly fire?
    • Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagonlike peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010;53:1-6.
    • (2010) Diabetologia , vol.53 , pp. 1-6
    • Butler, P.C.1    Matveyenko, A.V.2    Dry, S.3    Bhushan, A.4    Elashoff, R.5
  • 82
    • 77953192546 scopus 로고    scopus 로고
    • An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials
    • Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, et al. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab 2010;12:495-509
    • (2010) Diabetes Obes Metab , vol.12 , pp. 495-509
    • Ligueros-Saylan, M.1    Foley, J.E.2    Schweizer, A.3    Couturier, A.4
  • 83
    • 33748316958 scopus 로고    scopus 로고
    • Sustained Reduction in HbA1c during One-Year Treatment With Vildagliptin in Patients with Type 2 Diabetes (T2DM)
    • Degager S, Lebeaut A, Couturier A, Schweizer A. Sustained Reduction in HbA1c during One-Year Treatment With Vildagliptin in Patients with Type 2 Diabetes (T2DM). Diabetes 2006;55(suppl 1):A29
    • (2006) Diabetes , vol.55 , Issue.SUPPL. 1
    • Degager, S.1    Lebeaut, A.2    Couturier, A.3    Schweizer, A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.